ALLIANCES (Pfizer) (Details) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Alliances Statement [Line Items]
Percentage of third-party product sales recognized when BMS is the principal in the end customer sale	100.00%								100.00%
Net product sales									$ 14,045	$ 11,660	$ 12,304
Alliance revenues									2,515	4,219	4,081
Total Revenues	$ 4,287	$ 4,069	$ 4,163	$ 4,041	$ 4,258	$ 3,921	$ 3,889	$ 3,811	16,560	15,879	16,385
Receivables - from alliance partners	958				888				958	888
Deferred income	1,589				1,937				1,589	1,937
Upfront payments for licensing and alliance arrangements									619
Deferred income - Cash flow									218	613	965
Eliquis [Member]
Alliances Statement [Line Items]
Total Revenues									1,860	774	146
Alliance Partners [Member]
Alliances Statement [Line Items]
Net product sales									4,308	3,531	4,417
Alliance revenues									2,408	3,828	3,804
Total Revenues									6,716	7,359	8,221
Payments to/(from) alliance partner - Cost of products sold									1,655	1,394	1,356
Payments to/(from) alliance partner - Marketing, selling and administrative									15	134	(183)
Payments to/(from) alliance partner - Research and development									693	8	(140)
Payments to/(from) alliance partners - Other (income)/expense									(733)	(1,076)	(313)
Noncontrolling interest, pre-tax									51	38	36
Receivables - from alliance partners	958				888				958	888
Accounts payable - to alliance partners	542				1,479				542	1,479
Deferred income	1,459				1,493				1,459	1,493
Pfizer [Member]
Alliances Statement [Line Items]
Net product sales									1,849	771	144
Alliance revenues									11	3	2
Total Revenues									1,860	774	146
Deferred income	$ 576				$ 611				576	611
Cost of products sold - Profit sharing									895	363	69
Cost reimbursements to/(from) alliance partner									15	26	4
Other (income)/expense - Amortization of deferred income									(55)	(50)	(41)
Deferred income - Cash flow									$ 20	$ 100	$ 205
Pfizer [Member] | Eliquis [Member]
Alliances Statement [Line Items]
Minimum percentage of reimbursement for development costs from alliance partner	50.00%								50.00%
Maximum percentage of reimbursement for development costs from alliance partner	60.00%								60.00%
Total upfront, milestone and other licensing payments received to date	$ 884								$ 884